[Special Stock] Hyundai ADM Rises on News of 100% Cancer Metastasis Inhibition Effect of Cancer Stem Cell Targeting Anticancer Drug

Hyundai ADM is showing strong performance. This is attributed to the announcement of research results indicating that a niclosamide-based anti-metastatic cancer drug targeting cancer stem cells demonstrated 100% efficacy in inhibiting cancer metastasis.

As of 9:18 AM on the 24th, Hyundai ADM is trading at 1,603 KRW, up 21.44% compared to the previous day.

On the 24th, Hyundai ADM announced the results of a non-small cell lung cancer animal model test conducted by CRO HLB BioStep. The test observed metastasis after 18 days of combined administration of Bevacizumab and the niclosamide-based anti-metastatic cancer drug.

As a result, cancer metastasis occurred in 66.6% of the Bevacizumab-only group, whereas in the niclosamide-based anti-metastatic drug combination group, metastasis occurred in 33.3% of the low-dose group (50 mg/kg), and no metastasis occurred in the medium-dose group (100 mg/kg) and high-dose group (150 mg/kg), confirming 100% efficacy in inhibiting cancer metastasis.

Conventional cancer treatments are effective in reducing tumor size initially, but during treatment, they can promote the stemness of cancer stem cells (CSCs), leading to drug resistance, cancer recurrence, and metastasis. Although anti-cancer drugs targeting cancer stem cells have not yet been developed, scientists have evaluated that the emergence of such drugs could mark a new turning point in cancer treatment.

Previous studies have shown that niclosamide effectively suppresses cancer stem cells by blocking major signaling pathways involved in cancer metastasis (Wnt/β-catenin, STAT3, PI3K/AKT, etc.). However, for over 60 years, it has not been repurposed as an anti-cancer drug due to challenges such as 'low absorption rate' and 'short duration of effective blood concentration.' Hyundai Bio, the largest shareholder of Hyundai ADM, overcame these two challenges by applying its patented drug delivery system technology to successfully repurpose niclosamide as an oral anti-metastatic cancer drug.

Through this animal experiment, Hyundai ADM revealed the potential of the niclosamide-based anti-metastatic cancer drug to fundamentally prevent cancer recurrence and metastasis by targeting cancer stem cells, and especially expects a strong synergistic effect when combined with existing treatments.

Kim Taek-seong, CEO of Hyundai ADM, stated, "We plan to further verify the therapeutic effects across various cancer types through future clinical trials," adding, "We will change the paradigm of cancer treatment with anti-cancer drugs targeting cancer stem cells."